BRPI0108386B8 - conjugado de uricase, composição farmacêutica e método para a purificação de uricase - Google Patents

conjugado de uricase, composição farmacêutica e método para a purificação de uricase

Info

Publication number
BRPI0108386B8
BRPI0108386B8 BRPI0108386A BR0108386A BRPI0108386B8 BR PI0108386 B8 BRPI0108386 B8 BR PI0108386B8 BR PI0108386 A BRPI0108386 A BR PI0108386A BR 0108386 A BR0108386 A BR 0108386A BR PI0108386 B8 BRPI0108386 B8 BR PI0108386B8
Authority
BR
Brazil
Prior art keywords
uricase
conjugate
purification
pharmaceutical composition
protein
Prior art date
Application number
BRPI0108386A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0108386B1 (pt
BR0108386A (pt
BR0108386C1 (pt
Inventor
David Williams L
S Hershfield Michael
G P Saifer Mark
R Sherman Merry
J Kelly Susan
Original Assignee
Univ Duke
Mountain View Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Mountain View Pharmaceuticals Inc filed Critical Univ Duke
Publication of BR0108386A publication Critical patent/BR0108386A/pt
Publication of BR0108386C1 publication Critical patent/BR0108386C1/pt
Publication of BR0108386B1 publication Critical patent/BR0108386B1/pt
Publication of BRPI0108386B8 publication Critical patent/BRPI0108386B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0108386A 2000-02-10 2001-02-07 conjugado de uricase, composição farmacêutica e método para a purificação de uricase BRPI0108386B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/501,730 US6783965B1 (en) 2000-02-10 2000-02-10 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PCT/US2001/040069 WO2001059078A2 (en) 2000-02-10 2001-02-07 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Publications (4)

Publication Number Publication Date
BR0108386A BR0108386A (pt) 2002-10-29
BR0108386C1 BR0108386C1 (pt) 2011-12-20
BR0108386B1 BR0108386B1 (pt) 2017-10-31
BRPI0108386B8 true BRPI0108386B8 (pt) 2021-05-25

Family

ID=23994789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0108386A BRPI0108386B8 (pt) 2000-02-10 2001-02-07 conjugado de uricase, composição farmacêutica e método para a purificação de uricase

Country Status (27)

Country Link
US (3) US6783965B1 (enExample)
EP (3) EP2196538B1 (enExample)
JP (2) JP5165826B2 (enExample)
KR (3) KR20070092329A (enExample)
CN (2) CN100491532C (enExample)
AT (1) ATE463576T1 (enExample)
AU (3) AU4997501A (enExample)
BE (1) BE2013C045I2 (enExample)
BR (1) BRPI0108386B8 (enExample)
CA (1) CA2398679C (enExample)
CY (3) CY1110142T1 (enExample)
CZ (1) CZ304864B6 (enExample)
DE (1) DE60141742D1 (enExample)
DK (3) DK2196538T3 (enExample)
ES (2) ES2343105T3 (enExample)
FR (1) FR13C0036I2 (enExample)
HU (1) HU227127B1 (enExample)
IL (3) IL151065A0 (enExample)
LU (1) LU92237I2 (enExample)
MX (1) MXPA02007545A (enExample)
NZ (1) NZ520434A (enExample)
PL (1) PL208064B1 (enExample)
PT (2) PT2305819E (enExample)
RU (3) RU2352354C2 (enExample)
TW (2) TWI322184B (enExample)
WO (1) WO2001059078A2 (enExample)
ZA (1) ZA200207206B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
IL141220A0 (en) * 1998-08-06 2002-03-10 Mountain View Pharmaceuticals Conjugates of peg-urate oxidase and use thereof
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
PT1588716E (pt) 1998-08-06 2011-05-25 Mountain View Pharmaceuticals Conjugados de peg-urato oxidase e sua utiliza??o
AU766421B2 (en) 1998-08-06 2003-10-16 Duke University Urate oxidase
DE60229958D1 (de) 2001-06-28 2009-01-02 Mountain View Pharmaceuticals Polymerstabilisierte proteinasen
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP1531791B1 (en) * 2002-06-07 2010-08-11 Dyax Corp. Prevention and reduction of ischemia
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
PT1625156E (pt) * 2003-05-12 2013-01-09 Affymax Inc Novos péptidos que se fixam ao receptor da eritropoietina
MXPA05012314A (es) * 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
WO2004101600A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP2314320A2 (en) * 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
LT3321359T (lt) 2005-04-11 2021-05-10 Horizon Pharma Rheumatology Llc Urato oksidazės variantinės formos ir jų panaudojimas
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2006110761A2 (en) * 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
WO2006125452A1 (en) * 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
JP5033177B2 (ja) * 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
EP2195010A4 (en) * 2007-08-21 2012-03-14 Genzyme Corp TREATMENT WITH INHIBITORS OF KALLIKREINE
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
PL398781A1 (pl) 2009-06-25 2012-11-19 Savient Pharmaceuticals, Inc. Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
US8940861B2 (en) 2010-04-08 2015-01-27 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
DK3003358T3 (da) * 2013-06-07 2021-06-21 Allena Pharmaceuticals Inc Sammensætninger og anordninger til dialyse
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
UA121211C2 (uk) 2014-03-14 2020-04-27 Аджіос Фармасьютикалз, Інк. Фармацевтична композиція, що містить тверду дисперсію, та спосіб лікування гострої мієлогенної/мієлоїдної лейкемії (гмл)
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
MX2017014547A (es) 2015-05-15 2018-03-15 Medimmune Llc Secuencias de uricasa mejoradas y metodos de tratamiento.
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
CA2994447A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3538135A4 (en) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CA3069197A1 (en) 2017-07-07 2019-01-10 Allena Pharmaceuticals, Inc. Recombinant uricase enzyme
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109055260B (zh) * 2018-08-08 2021-11-09 淮海工学院 弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
CA3139550A1 (en) * 2019-05-10 2020-11-19 Peg-Bio Biopharm Co., Ltd. (Chongqing) Polyethylene glycol-modified urate oxidase
BR112023002458A2 (pt) 2020-08-10 2023-05-02 Horizon Therapeutics Usa Inc Métodos de tratamento da gota
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
CN117051026A (zh) * 2022-05-06 2023-11-14 江苏恰瑞生物科技有限公司 一种特异性尿酸结合物固定化树脂及其制备方法和应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (enExample)
FR1529675A (fr) * 1967-03-29 1968-06-21 Applic Biochimiques Soc Et Urate oxydase à haute activité et sa préparation
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
CH651308A5 (de) 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
JPH085506B2 (ja) * 1986-08-25 1996-01-24 日東製器株式会社 缶容器
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5955336A (en) * 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
SU1730145A1 (ru) * 1990-05-04 1992-04-30 Всесоюзный научно-исследовательский институт текстильно-галантерейной промышленности Способ стабилизации уриказы
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
DK0575545T3 (da) * 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
WO1994023740A1 (en) * 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0730470B1 (en) * 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996017929A1 (en) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en) 1995-06-07 1998-12-29 Chiron Corporation Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
EP1007082B1 (en) 1997-01-15 2006-10-18 Phoenix Pharmacologics, Inc. Modified tumor necrosis factor
CA2333747C (en) * 1998-06-01 2008-02-19 Genentech, Inc. Separation of protein monomers by use of ion-exchange chromatography
IL141220A0 (en) 1998-08-06 2002-03-10 Mountain View Pharmaceuticals Conjugates of peg-urate oxidase and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT1588716E (pt) 1998-08-06 2011-05-25 Mountain View Pharmaceuticals Conjugados de peg-urato oxidase e sua utiliza??o
AU766421B2 (en) 1998-08-06 2003-10-16 Duke University Urate oxidase
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US9917514B2 (en) 2013-05-24 2018-03-13 Idt Europe Gmbh Non PWM digital DC-DC converter

Also Published As

Publication number Publication date
AU2009212900A1 (en) 2009-10-01
ES2343105T8 (es) 2013-07-15
BR0108386B1 (pt) 2017-10-31
ATE463576T1 (de) 2010-04-15
KR20020087934A (ko) 2002-11-23
RU2557318C2 (ru) 2015-07-20
CA2398679C (en) 2015-11-17
HU227127B1 (en) 2010-07-28
EP2196538A1 (en) 2010-06-16
FR13C0036I1 (fr) 2013-08-09
BR0108386A (pt) 2002-10-29
RU2281954C2 (ru) 2006-08-20
KR20070092329A (ko) 2007-09-12
JP2003521937A (ja) 2003-07-22
US8921064B2 (en) 2014-12-30
CY2013028I2 (el) 2015-11-04
LU92237I2 (fr) 2013-09-03
DK2196538T3 (en) 2015-01-05
CN101735991A (zh) 2010-06-16
CZ304864B6 (cs) 2014-12-17
ES2343105T3 (es) 2010-07-23
CN101735991B (zh) 2013-09-11
BR0108386C1 (pt) 2011-12-20
CN100491532C (zh) 2009-05-27
US20110287466A1 (en) 2011-11-24
ZA200207206B (en) 2003-05-06
CY2013028I1 (el) 2015-11-04
HK1155203A1 (en) 2012-05-11
JP5341945B2 (ja) 2013-11-13
HK1144701A1 (en) 2011-03-04
AU4997501A (en) 2001-08-20
DK2305819T3 (en) 2015-01-05
HUP0204544A2 (en) 2003-05-28
EP1254237B1 (en) 2010-04-07
HK1143989A1 (en) 2011-01-21
HK1056742A1 (zh) 2004-02-27
EP2305819B1 (en) 2014-11-12
HUP0204544A3 (en) 2007-05-02
PL358539A1 (en) 2004-08-09
US7927852B2 (en) 2011-04-19
MXPA02007545A (es) 2002-12-13
WO2001059078A2 (en) 2001-08-16
US20080057048A1 (en) 2008-03-06
RU2352354C2 (ru) 2009-04-20
EP2305819A1 (en) 2011-04-06
IL193365A0 (en) 2009-02-11
PT1254237E (pt) 2010-06-07
US6783965B1 (en) 2004-08-31
ES2524153T3 (es) 2014-12-04
PL208064B1 (pl) 2011-03-31
TWI322184B (en) 2010-03-21
CY1110142T1 (el) 2015-01-14
IL151065A (en) 2008-12-29
DE60141742D1 (de) 2010-05-20
CN1423699A (zh) 2003-06-11
BE2013C045I2 (enExample) 2020-06-24
KR100884724B1 (ko) 2009-02-19
AU2009212900B2 (en) 2011-12-08
RU2009104003A (ru) 2010-08-20
PT2305819E (pt) 2015-06-01
EP2196538B1 (en) 2014-10-01
RU2557318C9 (ru) 2015-09-10
WO2001059078A3 (en) 2002-03-07
NZ520434A (en) 2004-05-28
IL193365A (en) 2011-08-31
FR13C0036I2 (fr) 2014-05-16
EP1254237A2 (en) 2002-11-06
CA2398679A1 (en) 2001-08-16
RU2006107110A (ru) 2007-09-20
AU2001249975B2 (en) 2006-06-08
IL151065A0 (en) 2003-04-10
DK1254237T3 (da) 2010-07-19
KR20080098686A (ko) 2008-11-11
KR101054247B1 (ko) 2011-08-08
JP2011188861A (ja) 2011-09-29
CY1117264T1 (el) 2017-04-26
JP5165826B2 (ja) 2013-03-21
CZ20022982A3 (cs) 2003-01-15
TW200914617A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
BRPI0108386B8 (pt) conjugado de uricase, composição farmacêutica e método para a purificação de uricase
JPH06506248A (ja) 新規な非抗凝固剤ヘパリン誘導体
KR970706842A (ko) 아실화된 인슐린 동족체(Acylated Insulin Analogs)
BRPI0212999B1 (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
JPS62246520A (ja) 白内障の予防及び逆転方法及び眼の組成物
KR920700040A (ko) 내산성 fgf 조성물 및 위장관의 궤양성 질병의 치료방법
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
Gupta et al. Subunit structure of porcine submaxillary mucin
RU2007145202A (ru) Использование tfpi для лечения тяжелых бактериальных инфекций
US20230338471A1 (en) Liquid formulations comprising mutant fgf-21 peptide pegylated conjugates
ATE549036T1 (de) Thymosin-alpha-1-peptid/polymer-konjugate
JP7689573B2 (ja) ポリエチレングリコール修飾尿酸オキシダーゼの製造方法
AU5071902A (en) A complex comprising OCIF and polysaccharide
US20060275279A1 (en) Methods for dissolving cystine stones and reducing cystine in urine
JP2002533473A (ja) 微生物起源のヒアルロン酸分解酵素を含有する薬学的配合物
US4024247A (en) Composition and method of using a protein mixture derived from liver
Andersen et al. The effect of proteolytic enzymes on the vitamin B12-binding proteins of human gastric juice and saliva
AU755534B2 (en) Use of sulodexide and of the medicines containing it in the treatment of the diabetic retinopathy
CN102964442B (zh) 一种聚乙二醇同神经生长因子结合物的制备方法
WO1994008595A1 (en) Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
Hoskins The ABO blood group antigens and their secretion by healthy and diseased gastric mucosa
JPH02238879A (ja) Ｎ―ポリオシル―ポリペプチド
WO1992017506A1 (en) MODULATION OF tPA ACTIVITY BY HEPARIN FRAGMENTS
Luvisetto Hyperthyroidism and mitochondrial uncoupling
EP1015483B1 (en) Malaria polypeptides

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: A FIM DE ATENDER AO SOLICITADO NA PETICAO DE ESCLARECIMENTO NO 018090054813-SP, DE 10/12/2009, DEVERA O TITULAR APRESENTAR ATRAVES DE FORMULARIO PROPRIO A SOLICITACAO DE TRANSFERENCIA PARCIAL DE TITULARIDADE.

B25A Requested transfer of rights approved

Owner name: MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) , DUKE UN

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: MOUNTAIN VIEW PHARMACEUTICALS, INC.

B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: A PETICAO DE NO 18120022985-SP, APRESENTADA EM 26/06/2012, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA, UMA VEZ QUE O SERVICO REQUERIDO REFERE-SE APENAS AO TITULAR DO DEPOSITO DE PATENTE OU DO PEDIDO DE PATENTE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/06 , A61K 47/48 , A61K 38/44

Ipc: A61K 38/44 (2006.01), C12N 9/06 (2006.01), C12N 9/

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 18120022984, APRESENTADA EM 26/06/2012, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA POR AUSENCIA DE FUNDAMENTACAO LEGAL, UMA VEZ QUE O INPI NAO FAZ ANOTACOES DE ENDERECO DE INVENTOR.

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25B Requested transfer of rights rejected

Owner name: MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) , DUKE UN

B25H Request for change of headquarter rejected

Owner name: MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) , DUKE UN

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 38/44

Ipc: A61K 47/60 (2017.01), C12N 9/06 (2006.01), C12N 9/

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 38/44; C12N 9/06; C12N 9/96; A61K 47/48.

Ipc: A61K 47/60 (2017.01), C12N 9/06 (2006.01), C12N 9/

Ipc: A61K 47/60 (2017.01), C12N 9/06 (2006.01), C12N 9/

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE A 20A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 07/02/2021

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: